natgillin/translations-raw huggingface dataset:
PegIntron is available in different pack sizes:
Zdravilo PegIntron je na voljo v različnih velikostih pakiranj:
PegIntron is likely to also cause this effect.
Verjetno ima tudi zdravilo PegIntron enak učinek.
PegIntron is recommended for use in fertile women only when they are using effective contraception during the treatment.
Zdravilo PegIntron priporočamo za uporabo pri plodnih ženskah le, če med zdravljenjem uporabljajo učinkovito kontracepcijo.
PegIntron is supplied as:
PegIntron je na voljo v naslednjih pakiranjih:
PegIntron is supplied as:
Zdravilo PegIntron je na voljo v naslednjih pakiranjih:
PegIntron monotherapy
PegIntron monoterapija
PegIntron monotherapy – Adults Dose to be administered
Monoterapija z zdravilom PegIntron – odrasli bolniki Odmerek za injiciranje
PegIntron pharmacodynamics were assessed in a rising single-dose trial in healthy subjects by examining changes in oral temperature, concentrations of effector proteins such as serum neopterin and 2’5’- oligoadenylate synthetase (2’5’-OAS), as well as white cell and neutrophil counts.
Farmakodinamiko zdravila PegIntron so ocenjevali v preskušanju pri zdravih preiskovancih z uporabo naraščajočih enkratnih odmerkov in merjenjem sprememb temperature v ustih in koncentracije efektorskih proteinov, kot sta serumski neopterin ter 2’5’-oligoadenilatsintetaza (2’5’-OAS), ter določanjem števila levkocitov in nevtrofilcev.
PegIntron strength (µg/0.5 ml)
Jakost zdravila PegIntron (g/0,5 ml)
PegIntron strength (g/0.5 ml)
Jakost zdravila PegIntron (µg/0,5 ml)
PegIntron supplied as:
Zdravilo PegIntron je na voljo v naslednjih pakiranjih:
PegIntron will be given in combination with ribavirin.
Zdravilo PegIntron se uporablja v kombinaciji z ribavirinom.
Pegloticase 8 mg every 2 weeks
peglotikaza 8 mg vsaka 2 tedna
Pegloticase 8 mg every 4 weeks
peglotikaza 8 mg vsake 4 tedne
Pegvisomant binds to growth hormone receptors on cell surfaces, where it blocks growth hormone binding, and thus interferes with intracellular growth hormone signal transduction.
Pegvisomant se veže na receptorje za rastni hormon na površini celic, s tem prepreči vezavo rastnega hormona in tako ovira znotrajcelični prenos signalov rastnega hormona.
Pegvisomant is not recommended during pregnancy (see section 4.6).
Med nosečnostjo pegvisomanta ni priporočljivo uporabljati (glejte poglavje 4.6).
Pegylated bovine granulocyte colony stimulating factor
Pegilirani faktor, ki
Pegylated interferon and ribavirin have
Pegilirani interferon in ribavirin nista
Pegylated liposomal doxorubicin is administered at 30 mg/m² on day 4 of the Bortezomib Accord treatment cycle as a 1 hour intravenous infusion administered after the Bortezomib Accord injection.
Pegilirani liposomski doksorubicin se daje v obliki 1-urne intravenske infuzije v odmerku 30 mg/m² na 4. dan kroga zdravljenja, po injiciranju zdravila Bortezomib Accord.
Pegylated liposomal doxorubicin is administered at 30 mg/m² on day 4 of the Bortezomib Hospira treatment cycle as a 1 hour intravenous infusion administered after the Bortezomib Hospira injection.
Pegilirani liposomski doksorubicin se daje v obliki 1-urne intravenske infuzije v odmerku 30 mg/m² na dan kroga zdravljenja, po injiciranju zdravila Bortezomib Hospira.
Pelleting conditions involve a single pre-conditioning step with steam for 5 minutes and pelleting at not more than 70 C under normal conditions.
Peletiranje obsega 5-minutno predpripravo v enem koraku s paro in peletiranje pri največ 70 C pod normalnimi pogoji.
Pelvic discomfort
neugodje v medenici
Pelvic haemorrhage
krvavitev v medenici
Pelvic pain
bolečina v medenici
Pelvic pain
bolečine v medenici
Pelvic pain
bolečine v medenici;
Pelvic pain
bolečine v predelu medenice
Pelvic pain
holelitiaza
Pelvic pain
Pogosti
pelvic pain, discharge, itching or pain in the vagina
bolečina v medenici, izcedek iz nožnice, srbenje ali bolečina v nožnici,
pelvic pain, discharge, itching or pain in the vagina
bolečina v medenici, izcedek iz nožnice, srbenje ali bolečina v nožnici;
pelvic surgery. removal of all or part of the prostate gland in which nerves of the prostate are cut (radical non nerve- sparing prostatectomy).
operacijo v medenici. odstranitev celotne prostate ali dela prostate, pri kateri so bili živci prostate prerezani (radikalna prostatektomija brez ohranjanja živcev).
pelvic surgery. removal of all or part of the prostate gland in which nerves of the prostate are cut (radical non- nerve-sparing prostatectomy).
operacijo v medenici. odstranitev celotne prostate ali dela prostate, pri kateri so bili živci prostate prerezani (radikalna prostatektomija brez ohranjanja živcev).
Pelzont (1000 mg/20 mg to 2000 mg/40 mg at week 5)
Pelzont (1.000 mg/20 mg do 2.000 mg/40 mg 5. teden)
Pelzont 1,000 mg/20 mg modified-release tablets Nicotinic acid/laropiprant
Pelzont 1.000 mg/20 mg tablete s prirejenim sproščanjem nikotinska kislina/laropiprant
Pelzont 1,000 mg/20 mg modified-release tablets.
Pelzont 1.000 mg/20 mg tablete s prirejenim sproščanjem
Pelzont 1000 mg/20 mg modified-release tablets Nicotinic acid/laropiprant
Pelzont 1.000 mg/20 mg tablete s prirejenim sproščanjem nikotinska kislina/laropiprant
Pelzont contains nicotinic acid, which at therapeutic doses is a lipid-modifying agent, and laropiprant, a potent, selective antagonist of the prostaglandin D2 (PGD2) receptor subtype 1 (DP1).
Zdravilo Pelzont vsebuje nikotinsko kislino, ki v terapevtskih odmerkih vpliva na lipide, in laropiprant, močan, selektiven antagonist receptorja prostaglandina D2 (PGD2) podvrste 1 (DP1).
Pelzont is indicated for the treatment of dyslipidaemia, particularly in adult patients with combined mixed dyslipidaemia (characterised by elevated levels of LDL-cholesterol and triglycerides and low HDL-cholesterol) and in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial).
Zdravilo Pelzont je indicirano za zdravljenje dislipidemije, zlasti pri odraslih bolnikih s kombinirano mešano dislipidemijo (za katero so značilni zvišani LDL holesterol in trigliceridi in nizek HDL holesterol), in pri odraslih bolnikih s primarno hiperholesterolemijo (heterozigotno družinsko in nedružinsko).
Pelzont is not recommended in pregnancy unless clearly necessary.
Zdravila Pelzont v nosečnosti ne priporočamo, razen če je nujno potrebno.
Pelzont is used in addition to diet and exercise in patients with dyslipidaemia (abnormally high levels of fat in the blood), particularly ‘combined mixed dyslipidaemia’ and ‘primary hypercholesterolaemia’.
Zdravilo Pelzont se uporablja kot dodatek k prehrani in telesni vadbi pri bolnikih z dislipidemijo (nenormalno visoka raven maščobe v krvi), zlasti pri tistih s kombinirano mešano dislipidemijo in primarno hiperholesterolemijo.
Pelzont is used in addition to diet to lower your ‘bad’ cholesterol level.
Zdravilo Pelzont se uporablja poleg diete za: znižanje "slabega" holesterola.
Pelzont: No studies have been performed in paediatric patients.
Pelzont: Študij pri pediatričnih bolnikih niso izvedli.
Pelzont: Use in patients with hepatic insufficiency has not been studied.
Pelzont: Uporaba pri bolnikih z jetrno insuficienco ni raziskana.
Pembrolizumab 10 mg/kg every
Pembrolizumab 10 mg/kg na
Pembrolizumab 2 mg/kg every
Pembrolizumab 2 mg/kg na
Pembrolizumab 2 mg/kg every 3 weeks in patients naïve to treatment with ipilimumab n=51
Pembrolizumab 2 mg/kg na 3 tedne pri bolnikih, ki predhodno niso prejemali ipilimumaba n = 51
Pembrolizumab 2 mg/kg every 3 weeks in patients previously treated with ipilimumab n=89
Pembrolizumab 2 mg/kg na 3 tedne pri bolnikih, ki so predhodno prejemali ipilimumab n = 89
Pembrolizumab has been designed to attach to and block a receptor called PD-1, which switches off the activity of certain cells of the immune system (the body’s natural defences) called T cells.
Pembrolizumab so razvili tako, da se veže na receptor, ki izklopi dejavnost nekaterih celic imunskega sistema (naravne obrambe telesa), imenovanih celice T, in ga zavre.
Pembrolizumab is dosed via the intravenous route and therefore is immediately and completely bioavailable.
Pembrolizumab se uporablja intravensko, zato je njegova biološka uporabnost takojšnja in popolna.
Pembrolizumab may have a minor influence on the ability to drive and use machines.
Pembrolizumab ima lahko blag vpliv na sposobnost vožnje in upravljanja s stroji.
Pembrolizumab must be permanently discontinued for any Grade 3 immune related adverse reaction that recurs and for any Grade 4 immune related adverse reaction toxicity (see sections 4.2 and 4.8).
Pembrolizumab je treba trajno ukiniti, če se kateri koli imunsko pogojeni neželeni učinek 3. stopnje znova pojavi oziroma če se pojavi toksičen imunsko pogojeni neželeni učinek 4. stopnje (glejte poglavji 4.2 in 4.8).
Pemetrexed
EU/1/16/1115/002 Pemetreksed
Pemetrexed (N = 265)
Pemetreksed N = 265
pemetrexed / cisplatin (N = 226)
pemetreksed / cisplatin (N = 226)
Pemetrexed / Cisplatin (N = 226)
pemetreksed/ cisplatin (N = 226)
Pemetrexed Accord
Pemetreksed Accord
Pemetrexed Accord 100 mg contains less than 1 mmol sodium (23 mg) sodium per vial, i.e. essentially ‘sodium-free’.
Zdravilo Pemetreksed Accord 100 mg vsebuje manj kot 1 mmol (23 mg) natrija na vialo, kar v bistvu pomeni »brez natrija«.
Pemetrexed Accord 100 mg powder for concentrate for solution for infusion
Pemetreksed Accord 100 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed Accord 100 mg powder for concentrate for solution for infusion
Zdravilo Pemetreksed Accord 100 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed Accord 100 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed Accord 100 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed Accord 100 mg powder for concentrate for solution for infusion Pemetrexed Accord 500 mg powder for concentrate for solution for infusion Pemetrexed Accord 1000 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed Accord 100 mg prašek za koncentrat za raztopino za infundiranje Pemetreksed Accord 500 mg prašek za koncentrat za raztopino za infundiranje Pemetreksed Accord 1000 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed Accord 1000 mg powder for concentrate for solution for infusion
Pemetreksed Accord 1000 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed Accord 500 mg powder for concentrate for solution for infusion
Pemetreksed Accord 500 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed Accord is a ‘generic medicine’.
Zdravilo Pemetreksed Accord je „generično zdravilo“.
Pemetrexed Accord is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).
Zdravilo Pemetreksed Accord je indicirano kot monoterapija za zdravljenje lokalno napredovalega ali metastatskega nedrobnoceličnega pljučnega karcinoma, ki nima pretežno ploščatocelične histologije pri bolnikih, pri katerih bolezen ni napredovala neposredno po kemoterapiji na osnovi platine (glejte poglavje 5.1).
Pemetrexed Accord may make you feel tired.
Zdravilo Pemetreksed Accord lahko povzroči, da se boste počutili utrujene.
Pemetrexed Accord should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Zdravilo Pemetreksed Accord se daje kot 10-minutna intravenska infuzija prvi dan vsakega 21- dnevnega ciklusa.
Pemetrexed at a dose of 500 mg/m2 was studied as a single agent in 64 chemonaive patients with malignant pleural mesothelioma.
Pemetreksed so kot edino učinkovino preučevali v odmerku 500 mg/m2 pri 64 bolnikih z malignim plevralnim mezoteliomom, ki predhodno še niso prejemali kemoterapije.
Pemetrexed at a dose of 500 mg/m2 was studied as a single-agent in 64 chemonaive patients with malignant pleural mesothelioma.
Pemetreksed kot edino učinkovino so preučevali v odmerku 500 mg/m2 pri 64 bolnikih z malignim plevralnim mezoteliomom, ki predhodno še niso prejemali kemoterapije.
Pemetrexed can have genetically damaging effects.
Pemetreksed ima lahko gensko škodljive učinke.
Pemetrexed can have genetically damaging effects.
Pemetreksed lahko ima gensko škodljive učinke.
Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed Fresenius Kabi 100 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed Fresenius Kabi 100 mg: Each vial contains 100 milligrams of pemetrexed (as pemetrexed diacid).
Pemetreksed Fresenius Kabi 100 mg: Vsaka viala vsebuje 100 miligramov pemetrekseda (kot pemetreksed diacid).
Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed Fresenius Kabi 500 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed Fresenius Kabi 500 mg: Each vial contains 500 milligrams of pemetrexed (as pemetrexed diacid).
Pemetreksed Fresenius Kabi 500 mg: Vsaka viala vsebuje 500 miligramov pemetrekseda (kot pemetreksed diacid).
Pemetrexed Fresenius Kabi as single agent
Zdravilo Pemetreksed Fresenius Kabi kot samostojno zdravilo
Pemetrexed Fresenius Kabi in combination with cisplatin
Zdravilo Pemetreksed Fresenius Kabi v kombinaciji s cisplatinom
Pemetrexed Fresenius Kabi is a powder for concentrate for solution for infusion in a glass vial.
Zdravilo Pemetreksed Fresenius Kabi je prašek za koncentrat za raztopino za infundiranje v stekleni viali.
Pemetrexed Fresenius Kabi is a ‘generic medicine’.
Zdravilo Pemetreksed Fresenius Kabi je „generično zdravilo“.
Pemetrexed Fresenius Kabi may make you feel tired.
Zdravilo Pemetreksed Fresenius Kabi lahko povzroči, da se boste počutili utrujene.
Pemetrexed has been shown to be clastogenic in the in vivo micronucleus test in the mouse.
Za pemetreksed so pokazali, da je klastogen v testu mikrojedra in vivo pri miših.
Pemetrexed Hospira 1,000 mg powder for concentrate for solution for infusion
Pemetreksed Hospira 1.000 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed Hospira 1,000 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed Hospira 1.000 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed Hospira 1,000 mg vials contain approximately 108 mg sodium per vial.
Pemetreksed Hospira 1.000 mg vsebuje približno 108 mg natrija v eni viali.
Pemetrexed Hospira 100 mg contains less than 1 mmol (23 mg) of sodium i.e. essentially ‘sodium free’.
Pemetreksed Hospira 100 mg vsebuje manj kot 1 mmol (23 mg) natrija, kar v bistvu pomeni "brez natrija".
Pemetrexed Hospira 100 mg contains less than 1 mmol (23 mg) of sodium i.e. essentially ‘sodium free’.
Zdravilo Pemetreksed Hospira 100 mg vsebuje manj kot 1 mmol (23 mg) natrija, kar v bistvu pomeni "brez natrija".
Pemetrexed Hospira 100 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed Hospira 100 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed Hospira 100 mg powder for concentrate for solution for infusion Pemetrexed Hospira 500 mg powder for concentrate for solution for infusion Pemetrexed Hospira 1,000 mg powder for concentrate for solution for infusion
Pemetreksed Hospira 100 mg prašek za koncentrat za raztopino za infundiranje Pemetreksed Hospira 500 mg prašek za koncentrat za raztopino za infundiranje Pemetreksed Hospira 1.000 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed Hospira 100 mg powder for concentrate for solution for infusion Pemetrexed Hospira 500 mg powder for concentrate for solution for infusion Pemetrexed Hospira 1,000 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed Hospira 100 mg prašek za koncentrat za raztopino za infundiranje Pemetreksed Hospira 500 mg prašek za koncentrat za raztopino za infundiranje Pemetreksed Hospira 1.000 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed Hospira 500 mg contains approximately 54 mg sodium per vial.
Zdravilo Pemetreksed Hospira 500 mg vsebuje približno 54 mg natrija na vialo.
Pemetrexed Hospira 500 mg powder for concentrate for solution for infusion
Pemetreksed Hospira 500 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed Hospira 500 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed Hospira 500 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed Hospira as single agent
Zdravilo Pemetreksed Hospira kot samostojno zdravilo
Pemetrexed Hospira in combination with cisplatin
Zdravilo Pemetreksed Hospira v kombinaciji s cisplatinom
Pemetrexed Hospira is a powder for concentrate for solution for infusion in a glass vial.
Pemetreksed je prašek za koncentrat za raztopino za infundiranje v stekleni viali.
Pemetrexed Hospira is a ‘generic medicine’.
Zdravilo Pemetreksed Hospira je „generično zdravilo“.
Pemetrexed Hospira is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).
Zdravilo Pemetreksed Hospira je indiciran0 kot monoterapija za zdravljenje lokalno napredovalega ali metastatskega nedrobnoceličnega pljučnega karcinoma, ki nima pretežno ploščatocelične histologije pri bolnikih, pri katerih bolezen ni napredovala neposredno po kemoterapiji na osnovi platine (glejte poglavje 5.1).
Pemetrexed Hospira may make you feel tired.
Pemetreksed Hospira lahko povzroči, da se boste počutili utrujene.
Pemetrexed Hospira should be administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Zdravilo Pemetreksed Hospira se daje kot 10-minutna intravenska infuzija prvi dan vsakega 21- dnevnega ciklusa.
Pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).
Pemetreksed je v kombinaciji s cisplatinom indicirana kot zdravljenje prvega izbora za bolnike z lokalno napredovalim ali metastatskim nedrobnoceličnim karcinomom pljuč, ki nima pretežno ploščatocelične histologije (glejte poglavje 5.1).
Pemetrexed infusion solutions prepared as directed above are compatible with polyvinyl chloride- and polyolefin- lined administration sets and infusion bags.
Raztopine pemetrekseda za infundiranje, pripravljene, kot je navedeno zgoraj, so skladne s seti za dajanje in infuzijskimi vrečkami iz polivinilklorida in prevlečenimi s poliolefinom.
Pemetrexed is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folate- dependent metabolic processes essential for cell replication.
Pemetreksed Sandoz (pemetreksed) je večtarčno protirakavo antifolatno zdravilo, ki deluje s porušenjem ključnih presnovnih procesov, odvisnih od folata, ki so nujni za podvajanje celic.
Pemetrexed is incompatible with diluents containing calcium, including lactated Ringer’s Injection and Ringer’s Injection.
Pemetreksed je inkompatibilen z vehikli, ki vsebujejo kalcij, vključno z raztopino Ringerjevega laktata za injiciranje in Ringerjevo raztopino za injiciranje.
Pemetrexed is incompatible with diluents containing calcium, including lactated Ringer’s Injection and Ringer’s Injection.
Pemetreksed je nekompatibilen z vehikli, ki vsebujejo kalcij, vključujoč raztopino Ringerjevega laktata ter Ringerjevo raztopino.
Pemetrexed is physically incompatible with diluents containing calcium, including lactated Ringer’s injection and Ringer’s injection.
Pemetreksed je fizikalno nekompatibilen z vehikli ki vsebujejo kalcij, vključujoč raztopino Ringerjevega laktata ter Ringerjevo raztopino.
Pemetrexed is physically incompatible with diluents containing calcium, including lactated Ringer’s injection and Ringer’s injection.
Pemetreksed je fizikalno nekompatibilen z vehikli, ki vsebujejo kalcij, vključujoč raztopino Ringerjevega laktata ter Ringerjevo raztopino.
Pemetrexed Lilly 100 mg powder for concentrate for solution for infusion Pemetrexed Lilly 500 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed Lilly 100 mg prašek za koncentrat za raztopino za infundiranje Pemetreksed Lilly 500 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed Lilly 100 mg: 1 vial of 10ml
Pemetreksed Lilly 100 mg: 1 viala prostornine 10 ml
Pemetrexed Lilly 500 mg powder for concentrate for solution for infusion
Pemetreksed Lilly 500 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed Lilly 500 mg: 1 vial of 50ml
Pemetreksed Lilly 500 mg: 1 viala prostornine 50 ml
Pemetrexed Lilly in combination with cisplatin
Pemetreksed Lilly v kombinaciji s cisplatinom
Pemetrexed Lilly is a powder for concentrate for solution for infusion in a glass vial with rubber stopper.
Pemetreksed Lilly je prašek za koncentrat za raztopino za infundiranje v stekleni viali z gumijastim zamaškom.
Pemetrexed Lilly is a ‘generic medicine’.
Zdravilo Pemetrexed Lilly je „generično zdravilo“.
Pemetrexed Lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).
Zdravilo Pemetreksed Lilly je indicirano kot monoterapija za zdravljenje lokalno napredovalega ali metastatskega nedrobnoceličnega pljučnega karcinoma, ki nima pretežno ploščatocelične histologije pri bolnikih, pri katerih bolezen ni napredovala neposredno po kemoterapiji na osnovi platine (glejte poglavje 5.1).
Pemetrexed Lilly may make you feel tired.
Zdravilo Pemetreksed Lilly lahko povzroči, da se boste počutili utrujene.
Pemetrexed medac
Pemetreksed medac
Pemetrexed medac 1,000 mg contains approximately 108 mg sodium per vial.
Zdravilo Pemetreksed medac 1000 mg vsebuje približno 108 mg natrija na vialo.
Pemetrexed medac 1,000 mg powder for concentrate for solution for infusion
Pemetreksed medac 1000 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed medac 1,000 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed medac 1000 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed medac 100 mg contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially ‘sodium-free’.
Zdravilo Pemetreksed medac 100 mg vsebuje manj kot 1 mmol natrija (23 mg) na vialo, kar v bistvu pomeni »brez natrija«.
Pemetrexed medac 100 mg powder for concentrate for solution for infusion
Pemetreksed medac 100 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed medac 100 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed medac 100 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed medac 100 mg powder for concentrate for solution for infusion Pemetrexed medac 500 mg powder for concentrate for solution for infusion Pemetrexed medac 1,000 mg powder for concentrate for solution for infusion
Pemetreksed medac 100 mg prašek za koncentrat za raztopino za infundiranje Pemetreksed medac 500 mg prašek za koncentrat za raztopino za infundiranje Pemetreksed medac 1000 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed medac 500 mg contains approximately 54 mg sodium per vial.
Zdravilo Pemetreksed medac 500 mg vsebuje približno 54 mg natrija na vialo.
Pemetrexed medac 500 mg powder for concentrate for solution for infusion
Pemetreksed medac 500 mg prašek za koncentrat za raztopino za infundiranje
Pemetrexed medac 500 mg powder for concentrate for solution for infusion pemetrexed
Pemetreksed medac 500 mg prašek za koncentrat za raztopino za infundiranje pemetreksed
Pemetrexed medac is a medicine used in the treatment of cancer.
Pemetreksed medac je zdravilo, ki ga uporabljamo pri zdravljenju raka.
Pemetrexed medac is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication.
Pemetreksed medac (pemetreksed) je večtarčno protirakavo antifolatno zdravilo, ki deluje s porušenjem ključnih presnovnih procesov, odvisnih od folata, ki so nujni za podvajanje celic.